During the past decade, Instituto D'Or de Pesquisa e Ensino (IDOR) conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 1 clinical trials were completed, i.e. on average, 3.4% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto D'Or de Pesquisa e Ensino (IDOR)" #1 sponsor was "Janssen Research & Development, LLC" with 18 trials, followed by "Pfizer" with 4 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Latin American Cooperative Oncology Group" with 2 trials sponsored and "D'Or Institute for Research and Education" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto D'Or de Pesquisa e Ensino (IDOR)" #1 collaborator was "Astellas Pharma Inc" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Diagnosticos da America SA" with 1 trials as a collaborator, "HalioDx" with 1 trials as a collaborator and "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Instituto D'Or de Pesquisa e Ensino (IDOR)" are "Carcinoma, Non-Small-Cell Lung" (5 trials), "Multiple Myeloma" (2 trials), "Prostate Cancer" (2 trials), "Relapsed or Refractory Multiple Myeloma" (2 trials) and "Advanced Solid Tumor" (1 trials). Many other conditions were trialed in "Instituto D'Or de Pesquisa e Ensino (IDOR)" in a lesser frequency.

Most popular intervention types in "Instituto D'Or de Pesquisa e Ensino (IDOR)" are "Drug" (25 trials), "Biological" (2 trials), "Behavioral" (1 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Amivantamab" (5 trials), "Dexamethasone" (4 trials), "Lazertinib" (4 trials) and "Pomalidomide" (4 trials). Other intervention names were less common.

The vast majority of trials in "Instituto D'Or de Pesquisa e Ensino (IDOR)" are 25 trials for "All" genders, 4 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Instituto D'Or de Pesquisa e Ensino (IDOR)". undefined are not yet recruiting, 23 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Instituto D'Or de Pesquisa e Ensino (IDOR), undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Instituto D'Or de Pesquisa e Ensino (IDOR), 2 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".